Simeprevir and Sofosbuvir (SMV-SOF) for 12 Weeks for the Treatment of Chronic Hepatitis C Genotype 1 Infection: A Real World (Transplant) Hepatology Practice Experience
Combination treatment with SMV and SOF in genotype 1 chronic HCV patients achieved an overall SVR rate of 78% by ITT and 86% by per protocol. The presence of hepatocellular carcinoma was found to be a significant negative predictor of SVR12.

Related Post